Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ECG technology aims to spot hidden heart disease before the first heart attack

NCT ID NCT02814396

Diagnosis Sponsor: National Taiwan University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study evaluates a new multichannel ECG system designed to detect early signs of cardiovascular disease (CVD) in people who may have no symptoms yet. The system uses advanced algorithms to analyze electrical signals from the heart, looking for subtle abnormalities that could indicate future heart problems. Researchers aim to see if this portable device can diagnose CVD with good accuracy, potentially allowing earlier intervention.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a multichannel ECG analytic system with new algorithms
What this could lead to
If successful, this could enable earlier, portable detection of heart disease, potentially preventing heart attacks and other cardiovascular events.
What could go wrong
This is an early-stage diagnostic study, and the new system may not prove accurate enough for widespread use. Results need validation in larger, diverse populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 5,000 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Jan 2013

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Space ventricular repolarization within the proposal does not have to represent functions in heart health and disease. Repolarization dispersion higher than normal levels may allow early diagnosis of CVD. The BSPM and magnetic diagram (MCG) is a newly developed method for both records, and provide higher spatial resolution than conventional ECG signal but has a high cost and bulky shortcomings. It is impossible in a portable manner. Previously, the investigators have used a 64-channel low TC SQUID MCG equipment to develop and validate two parameters, the so-called QT interval (SIQTc) and T wave propagation (TWP) smoothness index, accurate detection and localization of myocardial ischemia blood.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients older than 20 years old. * with suspected arrhythmia or cardiovascular diseases. Exclusion criteria * NO

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arrhythmia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiac rhythm disease cardiovascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multichannel ecg system

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • NTUH

    RECRUITING

    Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.